CHAPTER 1: INTRODUCTION
1.1. Report description
1.2. Key market segments
1.3. Key benefits to the stakeholders
1.4. Research Methodology
1.4.1. Primary research
1.4.2. Secondary research
1.4.3. Analyst tools and models
CHAPTER 2: EXECUTIVE SUMMARY
2.1. CXO Perspective
CHAPTER 3: MARKET OVERVIEW
3.1. Market definition and scope
3.2. Key findings
3.2.1. Top impacting factors
3.2.2. Top investment pockets
3.3. Porter’s five forces analysis
3.3.1. Low bargaining power of suppliers
3.3.2. Low threat of new entrants
3.3.3. Low threat of substitutes
3.3.4. Low intensity of rivalry
3.3.5. Low bargaining power of buyers
3.4. Market dynamics
3.4.1. Drivers
3.4.1.1. Surge in technological advancement
3.4.1.2. Increase in urbanization and change in lifestyles
3.4.1.3. Increase in the prevalence of allergic conditions
3.4.2. Restraints
3.4.2.1. Potential side effects of chlorpheniramine maleate
3.4.2.2. Increase in shift towards alternative medicines
3.4.3. Opportunities
3.4.3.1. High growth potential in developing economies
3.5. COVID-19 Impact Analysis on the market
CHAPTER 4: CHLORPHENIRAMINE MALEATE MARKET, BY DOSAGE FORM
4.1. Overview
4.1.1. Market size and forecast
4.2. Tablets
4.2.1. Key market trends, growth factors and opportunities
4.2.2. Market size and forecast, by region
4.2.3. Market share analysis by country
4.3. Syrup
4.3.1. Key market trends, growth factors and opportunities
4.3.2. Market size and forecast, by region
4.3.3. Market share analysis by country
4.4. Eye Drops
4.4.1. Key market trends, growth factors and opportunities
4.4.2. Market size and forecast, by region
4.4.3. Market share analysis by country
CHAPTER 5: CHLORPHENIRAMINE MALEATE MARKET, BY APPLICATION
5.1. Overview
5.1.1. Market size and forecast
5.2. Allergy
5.2.1. Key market trends, growth factors and opportunities
5.2.2. Market size and forecast, by region
5.2.3. Market share analysis by country
5.3. Hay Fever (Allergic Rhinitis)
5.3.1. Key market trends, growth factors and opportunities
5.3.2. Market size and forecast, by region
5.3.3. Market share analysis by country
5.4. Common Cold
5.4.1. Key market trends, growth factors and opportunities
5.4.2. Market size and forecast, by region
5.4.3. Market share analysis by country
5.5. Watery Eyes
5.5.1. Key market trends, growth factors and opportunities
5.5.2. Market size and forecast, by region
5.5.3. Market share analysis by country
5.6. Itchy Throat/Skin
5.6.1. Key market trends, growth factors and opportunities
5.6.2. Market size and forecast, by region
5.6.3. Market share analysis by country
5.7. Anaphylactic Shock
5.7.1. Key market trends, growth factors and opportunities
5.7.2. Market size and forecast, by region
5.7.3. Market share analysis by country
5.8. Urticaria
5.8.1. Key market trends, growth factors and opportunities
5.8.2. Market size and forecast, by region
5.8.3. Market share analysis by country
CHAPTER 6: CHLORPHENIRAMINE MALEATE MARKET, BY DISTRIBUTION CHANNEL
6.1. Overview
6.1.1. Market size and forecast
6.2. Hospital Pharmacies
6.2.1. Key market trends, growth factors and opportunities
6.2.2. Market size and forecast, by region
6.2.3. Market share analysis by country
6.3. Retail Pharmacies
6.3.1. Key market trends, growth factors and opportunities
6.3.2. Market size and forecast, by region
6.3.3. Market share analysis by country
6.4. Online Pharmacies
6.4.1. Key market trends, growth factors and opportunities
6.4.2. Market size and forecast, by region
6.4.3. Market share analysis by country
CHAPTER 7: CHLORPHENIRAMINE MALEATE MARKET, BY REGION
7.1. Overview
7.1.1. Market size and forecast By Region
7.2. North America
7.2.1. Key trends and opportunities
7.2.2. Market size and forecast, by Dosage Form
7.2.3. Market size and forecast, by Application
7.2.4. Market size and forecast, by Distribution Channel
7.2.5. Market size and forecast, by country
7.2.5.1. U.S.
7.2.5.1.1. Key market trends, growth factors and opportunities
7.2.5.1.2. Market size and forecast, by Dosage Form
7.2.5.1.3. Market size and forecast, by Application
7.2.5.1.4. Market size and forecast, by Distribution Channel
7.2.5.2. Canada
7.2.5.2.1. Key market trends, growth factors and opportunities
7.2.5.2.2. Market size and forecast, by Dosage Form
7.2.5.2.3. Market size and forecast, by Application
7.2.5.2.4. Market size and forecast, by Distribution Channel
7.2.5.3. Mexico
7.2.5.3.1. Key market trends, growth factors and opportunities
7.2.5.3.2. Market size and forecast, by Dosage Form
7.2.5.3.3. Market size and forecast, by Application
7.2.5.3.4. Market size and forecast, by Distribution Channel
7.3. Europe
7.3.1. Key trends and opportunities
7.3.2. Market size and forecast, by Dosage Form
7.3.3. Market size and forecast, by Application
7.3.4. Market size and forecast, by Distribution Channel
7.3.5. Market size and forecast, by country
7.3.5.1. Germany
7.3.5.1.1. Key market trends, growth factors and opportunities
7.3.5.1.2. Market size and forecast, by Dosage Form
7.3.5.1.3. Market size and forecast, by Application
7.3.5.1.4. Market size and forecast, by Distribution Channel
7.3.5.2. France
7.3.5.2.1. Key market trends, growth factors and opportunities
7.3.5.2.2. Market size and forecast, by Dosage Form
7.3.5.2.3. Market size and forecast, by Application
7.3.5.2.4. Market size and forecast, by Distribution Channel
7.3.5.3. UK
7.3.5.3.1. Key market trends, growth factors and opportunities
7.3.5.3.2. Market size and forecast, by Dosage Form
7.3.5.3.3. Market size and forecast, by Application
7.3.5.3.4. Market size and forecast, by Distribution Channel
7.3.5.4. Italy
7.3.5.4.1. Key market trends, growth factors and opportunities
7.3.5.4.2. Market size and forecast, by Dosage Form
7.3.5.4.3. Market size and forecast, by Application
7.3.5.4.4. Market size and forecast, by Distribution Channel
7.3.5.5. Spain
7.3.5.5.1. Key market trends, growth factors and opportunities
7.3.5.5.2. Market size and forecast, by Dosage Form
7.3.5.5.3. Market size and forecast, by Application
7.3.5.5.4. Market size and forecast, by Distribution Channel
7.3.5.6. Rest of Europe
7.3.5.6.1. Key market trends, growth factors and opportunities
7.3.5.6.2. Market size and forecast, by Dosage Form
7.3.5.6.3. Market size and forecast, by Application
7.3.5.6.4. Market size and forecast, by Distribution Channel
7.4. Asia-Pacific
7.4.1. Key trends and opportunities
7.4.2. Market size and forecast, by Dosage Form
7.4.3. Market size and forecast, by Application
7.4.4. Market size and forecast, by Distribution Channel
7.4.5. Market size and forecast, by country
7.4.5.1. Japan
7.4.5.1.1. Key market trends, growth factors and opportunities
7.4.5.1.2. Market size and forecast, by Dosage Form
7.4.5.1.3. Market size and forecast, by Application
7.4.5.1.4. Market size and forecast, by Distribution Channel
7.4.5.2. China
7.4.5.2.1. Key market trends, growth factors and opportunities
7.4.5.2.2. Market size and forecast, by Dosage Form
7.4.5.2.3. Market size and forecast, by Application
7.4.5.2.4. Market size and forecast, by Distribution Channel
7.4.5.3. Australia
7.4.5.3.1. Key market trends, growth factors and opportunities
7.4.5.3.2. Market size and forecast, by Dosage Form
7.4.5.3.3. Market size and forecast, by Application
7.4.5.3.4. Market size and forecast, by Distribution Channel
7.4.5.4. India
7.4.5.4.1. Key market trends, growth factors and opportunities
7.4.5.4.2. Market size and forecast, by Dosage Form
7.4.5.4.3. Market size and forecast, by Application
7.4.5.4.4. Market size and forecast, by Distribution Channel
7.4.5.5. South Korea
7.4.5.5.1. Key market trends, growth factors and opportunities
7.4.5.5.2. Market size and forecast, by Dosage Form
7.4.5.5.3. Market size and forecast, by Application
7.4.5.5.4. Market size and forecast, by Distribution Channel
7.4.5.6. Rest of Asia-Pacific
7.4.5.6.1. Key market trends, growth factors and opportunities
7.4.5.6.2. Market size and forecast, by Dosage Form
7.4.5.6.3. Market size and forecast, by Application
7.4.5.6.4. Market size and forecast, by Distribution Channel
7.5. LAMEA
7.5.1. Key trends and opportunities
7.5.2. Market size and forecast, by Dosage Form
7.5.3. Market size and forecast, by Application
7.5.4. Market size and forecast, by Distribution Channel
7.5.5. Market size and forecast, by country
7.5.5.1. Brazil
7.5.5.1.1. Key market trends, growth factors and opportunities
7.5.5.1.2. Market size and forecast, by Dosage Form
7.5.5.1.3. Market size and forecast, by Application
7.5.5.1.4. Market size and forecast, by Distribution Channel
7.5.5.2. Saudi Arabia
7.5.5.2.1. Key market trends, growth factors and opportunities
7.5.5.2.2. Market size and forecast, by Dosage Form
7.5.5.2.3. Market size and forecast, by Application
7.5.5.2.4. Market size and forecast, by Distribution Channel
7.5.5.3. South Africa
7.5.5.3.1. Key market trends, growth factors and opportunities
7.5.5.3.2. Market size and forecast, by Dosage Form
7.5.5.3.3. Market size and forecast, by Application
7.5.5.3.4. Market size and forecast, by Distribution Channel
7.5.5.4. Rest of LAMEA
7.5.5.4.1. Key market trends, growth factors and opportunities
7.5.5.4.2. Market size and forecast, by Dosage Form
7.5.5.4.3. Market size and forecast, by Application
7.5.5.4.4. Market size and forecast, by Distribution Channel
CHAPTER 8: COMPETITIVE LANDSCAPE
8.1. Introduction
8.2. Top winning strategies
8.3. Product Mapping of Top 10 Player
8.4. Competitive Dashboard
8.5. Competitive Heatmap
8.6. Top player positioning, 2022
CHAPTER 9: COMPANY PROFILES
9.1. GlaxoSmithKline plc
9.1.1. Company overview
9.1.2. Key Executives
9.1.3. Company snapshot
9.1.4. Operating business segments
9.1.5. Product portfolio
9.1.6. Business performance
9.2. Bayer AG
9.2.1. Company overview
9.2.2. Key Executives
9.2.3. Company snapshot
9.2.4. Operating business segments
9.2.5. Product portfolio
9.2.6. Business performance
9.3. Merck & Co., Inc.
9.3.1. Company overview
9.3.2. Key Executives
9.3.3. Company snapshot
9.3.4. Operating business segments
9.3.5. Product portfolio
9.3.6. Business performance
9.4. Johnson & Johnson
9.4.1. Company overview
9.4.2. Key Executives
9.4.3. Company snapshot
9.4.4. Operating business segments
9.4.5. Product portfolio
9.4.6. Business performance
9.5. Alkem Laboratories Ltd.
9.5.1. Company overview
9.5.2. Key Executives
9.5.3. Company snapshot
9.5.4. Operating business segments
9.5.5. Product portfolio
9.5.6. Business performance
9.6. Viatris Inc.
9.6.1. Company overview
9.6.2. Key Executives
9.6.3. Company snapshot
9.6.4. Operating business segments
9.6.5. Product portfolio
9.6.6. Business performance
9.7. Zydus Lifesciences Limited
9.7.1. Company overview
9.7.2. Key Executives
9.7.3. Company snapshot
9.7.4. Operating business segments
9.7.5. Product portfolio
9.7.6. Business performance
9.8. Sun Pharmaceutical Industries Limited
9.8.1. Company overview
9.8.2. Key Executives
9.8.3. Company snapshot
9.8.4. Operating business segments
9.8.5. Product portfolio
9.8.6. Business performance
9.8.7. Key strategic moves and developments
9.9. Novalab Healthcare Pvt. Ltd.
9.9.1. Company overview
9.9.2. Key Executives
9.9.3. Company snapshot
9.9.4. Operating business segments
9.9.5. Product portfolio
9.10. Capellon Pharmaceuticals
9.10.1. Company overview
9.10.2. Key Executives
9.10.3. Company snapshot
9.10.4. Operating business segments
9.10.5. Product portfolio
TABLE 01. GLOBAL CHLORPHENIRAMINE MALEATE MARKET, BY DOSAGE FORM, 2022-2032 ($MILLION)
TABLE 02. CHLORPHENIRAMINE MALEATE MARKET FOR TABLETS, BY REGION, 2022-2032 ($MILLION)
TABLE 03. CHLORPHENIRAMINE MALEATE MARKET FOR SYRUP, BY REGION, 2022-2032 ($MILLION)
TABLE 04. CHLORPHENIRAMINE MALEATE MARKET FOR EYE DROPS, BY REGION, 2022-2032 ($MILLION)
TABLE 05. GLOBAL CHLORPHENIRAMINE MALEATE MARKET, BY APPLICATION, 2022-2032 ($MILLION)
TABLE 06. CHLORPHENIRAMINE MALEATE MARKET FOR ALLERGY, BY REGION, 2022-2032 ($MILLION)
TABLE 07. CHLORPHENIRAMINE MALEATE MARKET FOR HAY FEVER (ALLERGIC RHINITIS), BY REGION, 2022-2032 ($MILLION)
TABLE 08. CHLORPHENIRAMINE MALEATE MARKET FOR COMMON COLD, BY REGION, 2022-2032 ($MILLION)
TABLE 09. CHLORPHENIRAMINE MALEATE MARKET FOR WATERY EYES, BY REGION, 2022-2032 ($MILLION)
TABLE 10. CHLORPHENIRAMINE MALEATE MARKET FOR ITCHY THROAT/SKIN, BY REGION, 2022-2032 ($MILLION)
TABLE 11. CHLORPHENIRAMINE MALEATE MARKET FOR ANAPHYLACTIC SHOCK, BY REGION, 2022-2032 ($MILLION)
TABLE 12. CHLORPHENIRAMINE MALEATE MARKET FOR URTICARIA, BY REGION, 2022-2032 ($MILLION)
TABLE 13. GLOBAL CHLORPHENIRAMINE MALEATE MARKET, BY DISTRIBUTION CHANNEL, 2022-2032 ($MILLION)
TABLE 14. CHLORPHENIRAMINE MALEATE MARKET FOR HOSPITAL PHARMACIES, BY REGION, 2022-2032 ($MILLION)
TABLE 15. CHLORPHENIRAMINE MALEATE MARKET FOR RETAIL PHARMACIES, BY REGION, 2022-2032 ($MILLION)
TABLE 16. CHLORPHENIRAMINE MALEATE MARKET FOR ONLINE PHARMACIES, BY REGION, 2022-2032 ($MILLION)
TABLE 17. CHLORPHENIRAMINE MALEATE MARKET, BY REGION, 2022-2032 ($MILLION)
TABLE 18. NORTH AMERICA CHLORPHENIRAMINE MALEATE MARKET, BY DOSAGE FORM, 2022-2032 ($MILLION)
TABLE 19. NORTH AMERICA CHLORPHENIRAMINE MALEATE MARKET, BY APPLICATION, 2022-2032 ($MILLION)
TABLE 20. NORTH AMERICA CHLORPHENIRAMINE MALEATE MARKET, BY DISTRIBUTION CHANNEL, 2022-2032 ($MILLION)
TABLE 21. NORTH AMERICA CHLORPHENIRAMINE MALEATE MARKET, BY COUNTRY, 2022-2032 ($MILLION)
TABLE 22. U.S. CHLORPHENIRAMINE MALEATE MARKET, BY DOSAGE FORM, 2022-2032 ($MILLION)
TABLE 23. U.S. CHLORPHENIRAMINE MALEATE MARKET, BY APPLICATION, 2022-2032 ($MILLION)
TABLE 24. U.S. CHLORPHENIRAMINE MALEATE MARKET, BY DISTRIBUTION CHANNEL, 2022-2032 ($MILLION)
TABLE 25. CANADA CHLORPHENIRAMINE MALEATE MARKET, BY DOSAGE FORM, 2022-2032 ($MILLION)
TABLE 26. CANADA CHLORPHENIRAMINE MALEATE MARKET, BY APPLICATION, 2022-2032 ($MILLION)
TABLE 27. CANADA CHLORPHENIRAMINE MALEATE MARKET, BY DISTRIBUTION CHANNEL, 2022-2032 ($MILLION)
TABLE 28. MEXICO CHLORPHENIRAMINE MALEATE MARKET, BY DOSAGE FORM, 2022-2032 ($MILLION)
TABLE 29. MEXICO CHLORPHENIRAMINE MALEATE MARKET, BY APPLICATION, 2022-2032 ($MILLION)
TABLE 30. MEXICO CHLORPHENIRAMINE MALEATE MARKET, BY DISTRIBUTION CHANNEL, 2022-2032 ($MILLION)
TABLE 31. EUROPE CHLORPHENIRAMINE MALEATE MARKET, BY DOSAGE FORM, 2022-2032 ($MILLION)
TABLE 32. EUROPE CHLORPHENIRAMINE MALEATE MARKET, BY APPLICATION, 2022-2032 ($MILLION)
TABLE 33. EUROPE CHLORPHENIRAMINE MALEATE MARKET, BY DISTRIBUTION CHANNEL, 2022-2032 ($MILLION)
TABLE 34. EUROPE CHLORPHENIRAMINE MALEATE MARKET, BY COUNTRY, 2022-2032 ($MILLION)
TABLE 35. GERMANY CHLORPHENIRAMINE MALEATE MARKET, BY DOSAGE FORM, 2022-2032 ($MILLION)
TABLE 36. GERMANY CHLORPHENIRAMINE MALEATE MARKET, BY APPLICATION, 2022-2032 ($MILLION)
TABLE 37. GERMANY CHLORPHENIRAMINE MALEATE MARKET, BY DISTRIBUTION CHANNEL, 2022-2032 ($MILLION)
TABLE 38. FRANCE CHLORPHENIRAMINE MALEATE MARKET, BY DOSAGE FORM, 2022-2032 ($MILLION)
TABLE 39. FRANCE CHLORPHENIRAMINE MALEATE MARKET, BY APPLICATION, 2022-2032 ($MILLION)
TABLE 40. FRANCE CHLORPHENIRAMINE MALEATE MARKET, BY DISTRIBUTION CHANNEL, 2022-2032 ($MILLION)
TABLE 41. UK CHLORPHENIRAMINE MALEATE MARKET, BY DOSAGE FORM, 2022-2032 ($MILLION)
TABLE 42. UK CHLORPHENIRAMINE MALEATE MARKET, BY APPLICATION, 2022-2032 ($MILLION)
TABLE 43. UK CHLORPHENIRAMINE MALEATE MARKET, BY DISTRIBUTION CHANNEL, 2022-2032 ($MILLION)
TABLE 44. ITALY CHLORPHENIRAMINE MALEATE MARKET, BY DOSAGE FORM, 2022-2032 ($MILLION)
TABLE 45. ITALY CHLORPHENIRAMINE MALEATE MARKET, BY APPLICATION, 2022-2032 ($MILLION)
TABLE 46. ITALY CHLORPHENIRAMINE MALEATE MARKET, BY DISTRIBUTION CHANNEL, 2022-2032 ($MILLION)
TABLE 47. SPAIN CHLORPHENIRAMINE MALEATE MARKET, BY DOSAGE FORM, 2022-2032 ($MILLION)
TABLE 48. SPAIN CHLORPHENIRAMINE MALEATE MARKET, BY APPLICATION, 2022-2032 ($MILLION)
TABLE 49. SPAIN CHLORPHENIRAMINE MALEATE MARKET, BY DISTRIBUTION CHANNEL, 2022-2032 ($MILLION)
TABLE 50. REST OF EUROPE CHLORPHENIRAMINE MALEATE MARKET, BY DOSAGE FORM, 2022-2032 ($MILLION)
TABLE 51. REST OF EUROPE CHLORPHENIRAMINE MALEATE MARKET, BY APPLICATION, 2022-2032 ($MILLION)
TABLE 52. REST OF EUROPE CHLORPHENIRAMINE MALEATE MARKET, BY DISTRIBUTION CHANNEL, 2022-2032 ($MILLION)
TABLE 53. ASIA-PACIFIC CHLORPHENIRAMINE MALEATE MARKET, BY DOSAGE FORM, 2022-2032 ($MILLION)
TABLE 54. ASIA-PACIFIC CHLORPHENIRAMINE MALEATE MARKET, BY APPLICATION, 2022-2032 ($MILLION)
TABLE 55. ASIA-PACIFIC CHLORPHENIRAMINE MALEATE MARKET, BY DISTRIBUTION CHANNEL, 2022-2032 ($MILLION)
TABLE 56. ASIA-PACIFIC CHLORPHENIRAMINE MALEATE MARKET, BY COUNTRY, 2022-2032 ($MILLION)
TABLE 57. JAPAN CHLORPHENIRAMINE MALEATE MARKET, BY DOSAGE FORM, 2022-2032 ($MILLION)
TABLE 58. JAPAN CHLORPHENIRAMINE MALEATE MARKET, BY APPLICATION, 2022-2032 ($MILLION)
TABLE 59. JAPAN CHLORPHENIRAMINE MALEATE MARKET, BY DISTRIBUTION CHANNEL, 2022-2032 ($MILLION)
TABLE 60. CHINA CHLORPHENIRAMINE MALEATE MARKET, BY DOSAGE FORM, 2022-2032 ($MILLION)
TABLE 61. CHINA CHLORPHENIRAMINE MALEATE MARKET, BY APPLICATION, 2022-2032 ($MILLION)
TABLE 62. CHINA CHLORPHENIRAMINE MALEATE MARKET, BY DISTRIBUTION CHANNEL, 2022-2032 ($MILLION)
TABLE 63. AUSTRALIA CHLORPHENIRAMINE MALEATE MARKET, BY DOSAGE FORM, 2022-2032 ($MILLION)
TABLE 64. AUSTRALIA CHLORPHENIRAMINE MALEATE MARKET, BY APPLICATION, 2022-2032 ($MILLION)
TABLE 65. AUSTRALIA CHLORPHENIRAMINE MALEATE MARKET, BY DISTRIBUTION CHANNEL, 2022-2032 ($MILLION)
TABLE 66. INDIA CHLORPHENIRAMINE MALEATE MARKET, BY DOSAGE FORM, 2022-2032 ($MILLION)
TABLE 67. INDIA CHLORPHENIRAMINE MALEATE MARKET, BY APPLICATION, 2022-2032 ($MILLION)
TABLE 68. INDIA CHLORPHENIRAMINE MALEATE MARKET, BY DISTRIBUTION CHANNEL, 2022-2032 ($MILLION)
TABLE 69. SOUTH KOREA CHLORPHENIRAMINE MALEATE MARKET, BY DOSAGE FORM, 2022-2032 ($MILLION)
TABLE 70. SOUTH KOREA CHLORPHENIRAMINE MALEATE MARKET, BY APPLICATION, 2022-2032 ($MILLION)
TABLE 71. SOUTH KOREA CHLORPHENIRAMINE MALEATE MARKET, BY DISTRIBUTION CHANNEL, 2022-2032 ($MILLION)
TABLE 72. REST OF ASIA-PACIFIC CHLORPHENIRAMINE MALEATE MARKET, BY DOSAGE FORM, 2022-2032 ($MILLION)
TABLE 73. REST OF ASIA-PACIFIC CHLORPHENIRAMINE MALEATE MARKET, BY APPLICATION, 2022-2032 ($MILLION)
TABLE 74. REST OF ASIA-PACIFIC CHLORPHENIRAMINE MALEATE MARKET, BY DISTRIBUTION CHANNEL, 2022-2032 ($MILLION)
TABLE 75. LAMEA CHLORPHENIRAMINE MALEATE MARKET, BY DOSAGE FORM, 2022-2032 ($MILLION)
TABLE 76. LAMEA CHLORPHENIRAMINE MALEATE MARKET, BY APPLICATION, 2022-2032 ($MILLION)
TABLE 77. LAMEA CHLORPHENIRAMINE MALEATE MARKET, BY DISTRIBUTION CHANNEL, 2022-2032 ($MILLION)
TABLE 78. LAMEA CHLORPHENIRAMINE MALEATE MARKET, BY COUNTRY, 2022-2032 ($MILLION)
TABLE 79. BRAZIL CHLORPHENIRAMINE MALEATE MARKET, BY DOSAGE FORM, 2022-2032 ($MILLION)
TABLE 80. BRAZIL CHLORPHENIRAMINE MALEATE MARKET, BY APPLICATION, 2022-2032 ($MILLION)
TABLE 81. BRAZIL CHLORPHENIRAMINE MALEATE MARKET, BY DISTRIBUTION CHANNEL, 2022-2032 ($MILLION)
TABLE 82. SAUDI ARABIA CHLORPHENIRAMINE MALEATE MARKET, BY DOSAGE FORM, 2022-2032 ($MILLION)
TABLE 83. SAUDI ARABIA CHLORPHENIRAMINE MALEATE MARKET, BY APPLICATION, 2022-2032 ($MILLION)
TABLE 84. SAUDI ARABIA CHLORPHENIRAMINE MALEATE MARKET, BY DISTRIBUTION CHANNEL, 2022-2032 ($MILLION)
TABLE 85. SOUTH AFRICA CHLORPHENIRAMINE MALEATE MARKET, BY DOSAGE FORM, 2022-2032 ($MILLION)
TABLE 86. SOUTH AFRICA CHLORPHENIRAMINE MALEATE MARKET, BY APPLICATION, 2022-2032 ($MILLION)
TABLE 87. SOUTH AFRICA CHLORPHENIRAMINE MALEATE MARKET, BY DISTRIBUTION CHANNEL, 2022-2032 ($MILLION)
TABLE 88. REST OF LAMEA CHLORPHENIRAMINE MALEATE MARKET, BY DOSAGE FORM, 2022-2032 ($MILLION)
TABLE 89. REST OF LAMEA CHLORPHENIRAMINE MALEATE MARKET, BY APPLICATION, 2022-2032 ($MILLION)
TABLE 90. REST OF LAMEA CHLORPHENIRAMINE MALEATE MARKET, BY DISTRIBUTION CHANNEL, 2022-2032 ($MILLION)
TABLE 91. GLAXOSMITHKLINE PLC: KEY EXECUTIVES
TABLE 92. GLAXOSMITHKLINE PLC: COMPANY SNAPSHOT
TABLE 93. GLAXOSMITHKLINE PLC: PRODUCT SEGMENTS
TABLE 94. GLAXOSMITHKLINE PLC: PRODUCT PORTFOLIO
TABLE 95. BAYER AG: KEY EXECUTIVES
TABLE 96. BAYER AG: COMPANY SNAPSHOT
TABLE 97. BAYER AG: PRODUCT SEGMENTS
TABLE 98. BAYER AG: PRODUCT PORTFOLIO
TABLE 99. MERCK & CO., INC.: KEY EXECUTIVES
TABLE 100. MERCK & CO., INC.: COMPANY SNAPSHOT
TABLE 101. MERCK & CO., INC.: PRODUCT SEGMENTS
TABLE 102. MERCK & CO., INC.: PRODUCT PORTFOLIO
TABLE 103. JOHNSON & JOHNSON: KEY EXECUTIVES
TABLE 104. JOHNSON & JOHNSON: COMPANY SNAPSHOT
TABLE 105. JOHNSON & JOHNSON: PRODUCT SEGMENTS
TABLE 106. JOHNSON & JOHNSON: PRODUCT PORTFOLIO
TABLE 107. ALKEM LABORATORIES LTD.: KEY EXECUTIVES
TABLE 108. ALKEM LABORATORIES LTD.: COMPANY SNAPSHOT
TABLE 109. ALKEM LABORATORIES LTD.: PRODUCT SEGMENTS
TABLE 110. ALKEM LABORATORIES LTD.: PRODUCT PORTFOLIO
TABLE 111. VIATRIS INC.: KEY EXECUTIVES
TABLE 112. VIATRIS INC.: COMPANY SNAPSHOT
TABLE 113. VIATRIS INC.: PRODUCT SEGMENTS
TABLE 114. VIATRIS INC.: PRODUCT PORTFOLIO
TABLE 115. ZYDUS LIFESCIENCES LIMITED: KEY EXECUTIVES
TABLE 116. ZYDUS LIFESCIENCES LIMITED: COMPANY SNAPSHOT
TABLE 117. ZYDUS LIFESCIENCES LIMITED: PRODUCT SEGMENTS
TABLE 118. ZYDUS LIFESCIENCES LIMITED: PRODUCT PORTFOLIO
TABLE 119. SUN PHARMACEUTICAL INDUSTRIES LIMITED: KEY EXECUTIVES
TABLE 120. SUN PHARMACEUTICAL INDUSTRIES LIMITED: COMPANY SNAPSHOT
TABLE 121. SUN PHARMACEUTICAL INDUSTRIES LIMITED: PRODUCT SEGMENTS
TABLE 122. SUN PHARMACEUTICAL INDUSTRIES LIMITED: PRODUCT PORTFOLIO
TABLE 123. SUN PHARMACEUTICAL INDUSTRIES LIMITED: KEY STRATERGIES
TABLE 124. NOVALAB HEALTHCARE PVT. LTD.: KEY EXECUTIVES
TABLE 125. NOVALAB HEALTHCARE PVT. LTD.: COMPANY SNAPSHOT
TABLE 126. NOVALAB HEALTHCARE PVT. LTD.: PRODUCT SEGMENTS
TABLE 127. NOVALAB HEALTHCARE PVT. LTD.: PRODUCT PORTFOLIO
TABLE 128. CAPELLON PHARMACEUTICALS: KEY EXECUTIVES
TABLE 129. CAPELLON PHARMACEUTICALS: COMPANY SNAPSHOT
TABLE 130. CAPELLON PHARMACEUTICALS: PRODUCT SEGMENTS
TABLE 131. CAPELLON PHARMACEUTICALS: PRODUCT PORTFOLIO
❖ 免責事項 ❖
http://www.globalresearch.jp/disclaimer
